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Introduction: Rheumatic diseases (RDs) are associated with different cancers; however, it is unclear whether
particular cancers are more prevalent in certain RDs. In the present study, we examined the relative incidence of
several cancers in a single homogeneous cohort of patients with different RDs.
Methods: Patients (N = 3,586) diagnosed with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE),
systemic sclerosis (SSc), dermatomyositis (DM) or polymyositis were included. Cancer diagnosis was based on
histopathology. The 2008 Korean National Cancer Registry served as the reference for calculating standardized
incidence ratios (SIRs).
Results: During the follow-up period of 31,064 person-years, 187 patients developed cancer. RA and SLE patients
showed an increased risk of non-Hodgkin’s lymphoma (SIR for RA patients = 3.387, 95% confidence interval
(CI) = 1.462 to 6.673; SIR for SLE patients = 7.408, 95% CI = 2.405 to 17.287). SLE patients also had a higher risk of
cervical cancer (SIR = 4.282, 95% CI = 1.722 to 8.824). SSc patients showed a higher risk of lung cancer (SIR = 4.917,
95% CI = 1.977 to 10.131). Endometrial cancer was increased only in patients with DM (SIR = 30.529, 95% CI = 3.697
to 110.283). RA patients had a lower risk for gastric cancer (SIR = 0.663, 95% CI = 0.327 to 0.998). The mean time
between the RD and cancer diagnoses ranged from 0.1 to 16.6 years, with the shortest time observed in patients
with DM (2.0 ± 2.1 years).
Conclusions: Different RDs are associated with particular cancers. Thus, cancer surveillance tailored to specific RDs
might be beneficial.Introduction
Rheumatic diseases (RDs) result from immune dysfunc-
tion, which leads to chronic systemic inflammation and
damage to multiple organs. Precancerous cells can
escape cancer surveillance associated with impaired
immune response [1]. Chronic inflammation, along with
the associated production of cytokines and growth
factors, may promote the progression of precancerous
cells to a clinically relevant cancer [2]. Indeed, there is a
robust link between cancer and RDs. Patients with
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stated.(SLE) and Sjögren’s syndrome (SS) have a higher risk of
developing lymphoma [3-5], and those with systemic
sclerosis (SSc) tend to have a higher risk of developing
lung cancer [6,7]. These studies suggest that the type of
RD a patient has is associated with an increased risk of
developing certain cancers. This may be due to the
nature of the underlying immune dysfunction and the
extent of involved organ damage.
However, previous studies have shown marked varia-
tions in the estimated incidence of cancer in patients
with the same type of RD. This is likely due to diffe-
rences in genetic background, environmental factors and
available treatment options. For example, patients with
dermatomyositis (DM) in Scandinavia show an increased
risk of lung or endometrial cancer [8], whereas those in
Taiwan show an increased risk of head and neck cancerLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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populations with the same RD. Taiwanese RA patients
have an increased risk of kidney and vaginal cancer, but
no such associations are observed in Japanese RA patients
[10,11]. In addition to the heterogeneity of the study
populations, the methodological differences in case ascer-
tainment likely contribute to the varying SIR estimates
across studies. Population-based studies using National
Health Insurance claims or hospital discharge registry data
might reveal rare cancers at the expense of diagnostic
accuracy of RDs and cancer, especially when longitudinal
follow-up data are not available. Thus, comparison of can-
cer incidences from multiple studies would not conclu-
sively address the question whether a particular RD is
associated with a higher risk of developing a certain
cancer. Our aim in the present study was to compare the
relative incidence of several common cancers in different
RDs in a single homogeneous cohort.
Methods
Patients
As patients with a rare or critical illness, including RDs and
cancer, are entitled to reimbursement of a majority of their
medical copayments, diagnosis of RDs and cancer is sub-
jected to comprehensive clinical and laboratory assessments
in Korea. Thus, when the same International Classification
of Diseases (ICD) codes are entered repeatedly over a cer-
tain period of time for billing and reimbursement purposes,
diagnosis of RD is accurate with a high probability.
We first selected patients with the same ICD-10 code for
a specific RD (that is, RA (M 05.X, M 06.X), SLE (M 32.X),
SSc (M 34.X), DM (M 33.0, 33.1, 33.9), PM (M 33.2)] for
more than 6 months during their longitudinal medical care
at Seoul National University Hospital (SNUH) between
January 2000 and April 2012. Next, the medical records of
all selected patients with a diagnosis of probable RD were
reviewed. Only the patients with a definitive RD diagnosis
who fulfilled the criteria for RA, SLE, SSc, DM or PM were
enrolled in this study (Additional file 1: Figure S1) [12-15].
Patients who developed cancer before or within 1 month of
RD diagnosis were excluded.
The 2008 Korean National Cancer Registry, provided by
the Ministry of Health and Welfare of Korea [16], was used
as the reference for calculating the standardized incidence
ratios (SIRs). The study was approved by the Institutional
Review Board (IRB) of SNUH. Obtaining a patient consent
was waived by the IRB, as this study involved no more than
minimal risk as a retrospective study and no identifiable
information was used.
Cancer diagnosis
Histopathology reports were available in all cancer cases.
A complete data set regarding cancer histopathology
was obtained from the medical records.Statistical analysis
The expected number of cancers was calculated by multi-
plying the number of patients in the study cohort by the
age- and sex-matched cancer incidence rate for Koreans
obtained from the 2008 Korean National Cancer Registry.
When a patient was diagnosed with two or more cancers
during follow-up, each was considered as an individual
event. The SIR was calculated as the ratio of the observed
to the expected number of cancers, and the 95% confi-
dence interval (95% CI) was calculated based on the
assumption that the observed findings followed a Poisson
distribution [17]. Analysis of variance or Student’s t-tests
were used for group comparisons as appropriate. The
results were expressed as the mean ± standard deviation.
A P-value ≤0.05 was considered statistically significant. All
analyses were performed using SPSS version 16.0 statis-
tical software (IBM SPSS, Chicago, IL, USA).
Results
Study population
A total of 3,586 patients (84.0% female) with a definitive
RD diagnosis were identified and enrolled in the study.
The mean duration of follow-up was 7.8 ± 4.5 years, with
a total follow-up of 31,064 person-years (PYs). All
patients were ethnic Koreans. The mean age at the time
of RD diagnosis was 45.9 ± 15.2 years. RA was the most
common diagnosis (2,104 patients; 58.7%), followed by
SLE (1,052; 29.3%), SSc (274; 7.6%), DM (107; 3.0%) and
PM (49; 1.4%). Of these, 185 patients were diagnosed
with a malignancy, and 2 patients had 2 cancers, with an
overall cancer incidence of 0.60/100 PYs. The mean time
between the RD diagnosis and that of cancer ranged
from 0.1 to 16.6 years, with the shortest time observed
in patients with DM (2.0 ± 2.1 years). Notably, 5 (50.5%)
of the 10 malignancies were diagnosed within 1 year of
the DM diagnosis (Table 1).
Cancer incidence
The incidence of cancer varied between patients with
different types of RD. Compared with the incidence in
the general population, the cancer incidence was higher
in patients with SLE (SIR = 1.555; 95% CI, 1.137 to
1.974) and DM (SIR = 2.602; 95% CI, 1.248 to 4.785), but
lower in patients with RA (SIR = 0.803; 95% CI, 0.65 to
0.955) (Figure 1).
Association between individual rheumatic diseases and
particular cancers
The SIR for NHL was increased in patients with RA
(SIR = 3.387; 95% CI, 1.462 to 6.673) and in patients with
SLE (SIR = 7.408; 95% CI, 2.405 to 17.287). The inci-
dence of cervical cancer was increased only in patients
with SLE (SIR = 4.282; 95% CI, 1.722 to 8.824), whereas
that of lung cancer was increased only in patients with SSc
Table 1 Demographic characteristics of the rheumatic disease patientsa
RA (n = 2,104) SLE (n = 1,052) SSc (n = 274) DM (n = 107) PM (n = 49)
Age at RD diagnosis, yr, mean (SD) 51.0 (13.3) 35.0 (13.4) 48.5 (14.0) 45.5 (13.4) 47.9 (13.7)
Sex, female (%) 1,716 (81.6) 935 (88.9) 240 (87.6) 81 (75.7) 40 (81.6)
Mean follow-up duration, yr (SD) 7.4 (4.2) 8.9 (4.8) 6.6 (4.5) 6.1 (4.8) 6.7 (4.8)
Total follow-up duration in person-years 17,436 10,410 2,088 758 372
Cancer, n (%) 106 (5.0) 53 (5.0) 16 (5.8) 10 (9.3) 2 (4.1)
Age at cancer diagnosis, yr, mean (SD) 62.8 (11.7) 47.3 (14.7) 55.5 (11.9) 58.1 (14.6) 65.8 (0.3)
Time between RD and cancer, yr, mean (SD) 5.0 (3.5) 7.4 (4.0) 5.8 (3.5) 2.0 (2.1) 5.0 (6.1)
aDM, Dermatomyositis; PM, Polymyositis; RA, Rheumatoid arthritis; RD, Rheumatic disease; SD, Standard deviation; SLE, Systemic lupus erythematosus;
SSc, Systemic sclerosis.
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of endometrial cancer was estimated only in patients
with DM (SIR = 30.529; 95% CI, 3.697 to 110.283). The
incidence of gastric cancer was estimated to be lower in
patients with RA (SIR = 0.663; 95% CI, 0.327 to 0.997)
(Table 2).
Discussion
Impaired immune surveillance in patients with auto-
immune disease might allow precancerous cells to grow,
thereby increasing the overall risk of developing a clinic-
ally relevant cancer [1]. Indeed, an association between
particular cancers and specific RDs has been reported, and
the risk of developing a specific cancer appears to vary
markedly depending on the RD [18,19]. However, as previ-
ous studies have shown marked variations in the esti-
mated incidence of the same cancer in patients with the
same RD, comparison of estimated SIRs from different
studies has limitations. To the best of our knowledge, theFigure 1 Cancer incidence in patients with rheumatic disease. The inc
erythematosus and dermatomyositis, but lower in those with rheumatoid a
Standardized incidence ratio; CI, Confidence interval.present study is the first in which the incidence of com-
mon cancers in a single homogeneous cohort of patients
with different RDs has been estimated and compared.
In line with previous reports, our data show that pa-
tients with RA and SLE, but not those with SSc, DM or
PM, had an increased risk of developing lymphoma, sug-
gesting that the strong activation of lymphoid tissue is a
driving force (similar to the finding that chronic viral
or bacterial infections increase the risk of developing
lymphoma) [20]. Indeed, overexpression of B lymphocyte
simulator (BLyS) is associated with lymphoproliferative
disorders in patients with SS [21]. Patients with RA and
SLE exhibit high levels of BLyS [22,23].
Consistent with prior studies, lung cancer risk was
higher in patients with SSc [24,25]. Reduced forced vital
capacity and pulmonary fibrosis are associated with an
increased risk of developing lung cancer, suggesting that
the extent of lung damage may predict subsequent can-
cer development [7]. In the present study, the incidenceidence of cancer was higher in patients with systemic lupus
rthritis, compared with that in the general population. SIR,
Table 2 Standardized incidence ratios for each cancer according to type of rheumatic diseasea
Site of cancer RA SLE SSc DM PM
Breast O/E 10/12.509 4/5.883 0/1.653 0/0.492 0/0.282
SIR (CI) 0.799 (0.304 to 1.295) 0.68 (0.185 to 1.741) 0 (0 to 2.231) 0 (0 to 7.492) 0 (0 to 13.088)
Cervical O/E 4/3.786 7/1.635 0/0.47 0/0.136 0/0.085
SIR (CI) 1.056 (0.288 to 2.705) 4.282 (1.722 to 8.824) 0 (0 to 7.846) 0 (0 to 27.198) 0 (0 to 43.353)
Colorectal O/E 13/18.514 5/3.933 1/1.803 0/0.491 0/0.386
SIR (CI) 0.702 (0.32 to 1.084) 1.271 (0.413 to 2.967) 0.555 (0.014 to 3.09) 0 (0 to 7.518) 0 (0 to 9.55)
Endometrial O/E 0/1.883 0/0.742 0/0.238 2/0.066 0/0.044
SIR (CI) 0 (0 to 1.959) 0 (0 to 4.974) 0 (0 to 15.512) 30.529 (3.697 to 110.283) 0 (0 to 84.476)
Lung O/E 14/15.667 0/2.637 7/1.424 2/0.363 0/0.319
SIR (CI) 0.894 (0.489 to 1.499) 0 (0 to 1.399) 4.917 (1.977 to 10.131) 5.514 (0.668 to 19.917) 0 (0 to 11.546)
NHL O/E 8/2.462 5/0.675 1/0.242 1/0.071 0/0.049
SIR (CI) 3.387 (1.462 to 6.673) 7.408 (2.405 to 17.287) 4.141 (0.105 to 23.071) 14.088 (0.357 to 78.491) 0 (0 to 74.764)
Stomach O/E 15/22.625 3/5.027 2/2.236 1/0.614 1/0.473
SIR (CI) 0.663 (0.327 to 0.998) 0.597 (0.123 to 1.744) 0.898 (0.109 to 3.245) 1.629 (0.041 to 9.076) 2.113 (0.054 to 11.774)
Thyroid O/E 14/14.957 11/7.111 0/1.829 1/0.633 0/0.318
SIR (CI) 0.936 (0.446 to 1.426) 1.547 (0.633 to 2.461) 0 (0 to 2.017) 1.58 (0.04 to 8.805) 0 (0 to 11.601)
aDM, dermatomyositis; E, expected cases; NHL, Non-Hodgkin’s lymphoma; O, observed cases; PM, polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis. Numbers in
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severe interstitial lung disease, appeared to be increased,
although the increase did not reach statistical significance.
The overall risk of developing cancer was lower for RA
patients, in part due to the lower incidence of stomach
cancer (Table 2). This is striking because stomach cancer
is common in Korea, with an incidence of 43.8 per
100,000, which is due, at least in part, to the high pre-
valence of Helicobacter pylori infection [26]. The lower
overall incidence of gastric cancer in RA patients could
be explained by the increased use of nonsteroidal anti-
inflammatory drugs (NSAIDs), which reduce proliferative
stimuli and may slow down the progression of a precan-
cerous lesion [27]. Wu et al. reported that regular NSAID
use for 6 months or longer was associated with a lower
risk of developing a gastric cancer [28]. In a pilot study,
we compared NSAID use between RA patients with gas-
tric cancer and those without cancer. Thirteen of fifteen
RA patients with gastric cancer and forty of forty-five age-
and sex-matched RA patients without gastric cancer took
NSAIDs on regular basis for 6 months or longer (86.7%
vs. 88.9%, P = 1.0 by Fisher’s exact test). Although we
could not confirm the protective effect of NSAIDs on
gastric cancer in our cohort, it is still possible that
gastrointestinal complaints associated with frequent use of
NSAIDs might lead to early diagnosis and eradication of
subclinical H. pylori infections in RA patients, thereby
reducing the overall incidence of gastric cancer.
A population-based study using data from Sweden,
Denmark and Finland showed that ovarian and cervical
cancers were particularly increased in DM and PM [8].
In our present study, such associations were not found.
Instead, a higher SIR for endometrial cancer was ob-
served in DM patients.
Strikingly, five of the ten DM patients developed cancer
within 1 year of their DM diagnosis (Additional file 1:
Table S1), with a mean time between RD and cancer
diagnosis of 2.0 ± 2.1 years as compared to 7.4 ± 4.2 years,
8.9 ± 4.8 years and 6.6 ± 4.5 years for RA, SLE and SSc
patients, respectively. The tight temporal relationship
between DM and cancer suggests that a DM subset might
be triggered as an immunologic response to cancer, simi-
lar to what is seen in SSc patients with autoantibodies
against RNA polymerase III. In those SSc patients, cancer
was detected before or simultaneously with their SSc
diagnosis, and their peripheral T cells reacted to the pep-
tides derived from mutated RNA polymerase III [29]. It is
tempting to speculate that preclinical malignancies may
initiate and drive the development of DM through mo-
lecular mimicry between mutated cancer protein and
self-antigen, because treatment of the underlying cancer
has been reported to improve DM [30].
There was no association between thyroid cancer and
RD or between breast cancer and RD, and their SIRswere similar across RD as well (Table 2). It appears that
having RD does not increase the risk of developing
cancers that are common in the general population,
particularly if the cancer site is not an organ affected by
the systemic inflammation associated with RD.
A strength of the present study as a single center study
is the homogeneity of study population and the high
quality of the clinical data obtained in conjunction with
a relatively long follow-up of 31,064 PYs. This study
design allowed us to better estimate the “pure” effect of
individual RDs on cancer development. However, our
study has several limitations. Compared to a population-
based study, the cohort size was relatively small, with a
wide CI for SIR estimates and a low sensitivity for de-
tecting rare cancers. Because our hospital is a major ter-
tiary referral center, the patients in our cohort may have
had more severe disease and multiple comorbidities;
therefore, they may have been monitored more closely
and treated more quickly or differently, thereby leading
to possible treatment bias. As this was a retrospective
study, another limitation is that information on the
cancer in some patients with RD could not be captured
completely, especially when patients received their can-
cer treatment outside our center, possibly contributing
to the lower SIR of cancers in patients with RD. Last but
not least, we did not examine the treatment effects on
cancer development. For example, pulmonary fibrosis
may be a side effect of methotrexate and can predispose
a patient to developing lung cancer. Cyclophosphamide
can induce the development of secondary cancers [31].
In addition, the prolonged use of corticosteroids and
immunosuppressants can increase infection rates, which
may then increase cancer risk [32].Conclusions
Different RDs appear to be associated with particular
cancers. Therefore, RD patients might benefit from cancer
surveillance that is tailored to their RD.Additional file
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